Key facts
- This page summarizes Stephen H. Rusckowski's Form 4 filing for QUEST DIAGNOSTICS INC (DGX).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 08 Mar 2023, 15:29.
Stephen H. Rusckowski - 06 Mar 2023 Form 4 Insider Report for QUEST DIAGNOSTICS INC (DGX)
- Reporting relationship
- Director
- Issuer ticker
- DGX
- Reported as of
- 06 Mar 2023
- Net transaction value
- +$6,509,832
- SEC form
- 4
- Accepted by SEC
- 08 Mar 2023, 15:29:53 UTC
- Prior SEC filing
- 03 Mar 2023
- Next SEC filing
- 30 May 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ William J. O'Shaughnessy, Jr., Attorney in Fact for Stephen H. Rusckowski
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Stephen H. Rusckowski filed Form 4 for QUEST DIAGNOSTICS INC (DGX) on 08 Mar 2023.
Change
- Previous filing in this sequence was filed on 03 Mar 2023.
- Current net transaction value: +$6,509,832.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DGX
transaction
Common Stock
Award
- Transaction value
- $12,217,820
- Shares
- +82,631
- Change %
- +24%
- Price
- $147.86
- Shares after
- 428,201
- Date
- 06 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F2
DGX
transaction
Common Stock
Tax liability
- Transaction value
- $5,707,987
- Shares
- -38,604
- Change %
- -9%
- Price
- $147.86
- Shares after
- 389,597
- Date
- 06 Mar 2023
- Ownership
- Direct
- Footnotes
- F1, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Represents an award of restricted share units granted on February 25, 2013.
Footnote F2
Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d).
Footnote F3
Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.